OAS1: The Cost of Host Defense
Monday, 13 June 2022
OAS1 (Oligoadenylate synthetase 1) is induced by type 1 interferon signaling. It recognizes 18 bp (or longer) double stranded RNA segments from invading viruses in the cytosol and catalyzes the production of 2’-5’ linked oligoadenylate (2-5A) from ATP. The 2-5A then, at the expense of yet more ATP, exclusively activates endoribonclease L (RNase L) by
- Published in Emerging Targets, HTS Assays, Innate Immunity, Products
Exploring the Use of NUDT5 Inhibitors to Treat Breast Cancer
Monday, 23 August 2021
NUDT5 is found to be overexpressed in certain cancers in humans Could NUDT5 inhibitors lead to new cancer treatments? NUDIX hydrolases are a superfamily of enzymes are found in all classes of organisms and are responsible for hydrolyzing modified nucleoside diphosphates. One of the most well-studied NUDIX hydrolases is NUDT1 (also known as MTH1); it
- Published in Emerging Targets, HTS Assays, Products
JAK3 Inhibitors in the Treatment of Autoimmune Disease
Tuesday, 27 July 2021
Autoimmune disorders such as multiple sclerosis, psoriasis, and rheumatoid arthritis (RA), just to name a few, affect millions of people and have various contributing factors that lead to disease; some known and some unknown. These disorders occur due to the immune system’s failure to discriminate between self vs. foreign entities. Janus Kinase 3 (JAK3) is
- Published in Innate Immunity, Products
A Kinase Assay Kit to Interrogate Innate Immunity Targets
Thursday, 15 April 2021
Kinases are essential players in cellular functions such as cell signaling, cellular transport, and protein regulation. For these reasons, many kinases are innate immunity targets. A kinase assay kit is ideal whether used for drug screening and dose-response measurements or detection when studying a particular cellular pathway. A universal ADP assay allows researchers to screen
- Published in HTS Assays, Products
Small GTPase Modulation: GDP Assays to Accelerate Discovery
Wednesday, 24 March 2021
Cancer is complex, which makes determining the culprit as well as individual treatment extremely challenging. A variety of cancer types exist with a multitude of contributors. As the second leading cause of death in the US, cancer has been a target scientists have been battling for decades. When DNA is damaged or mutations occur, cells
- Published in HTS Assays, Products
New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay
Thursday, 10 December 2020
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
New Transcreener UDP2 Assay with a Fluorescence Intensity Readout
Friday, 29 May 2020
BellBrook Labs scientists have developed a new universal UDP detection assay for the measurement of Glycosyltransferase activity. The Transcreener UDP2 FI Assay extends the Transcreener platform for UDP detection by utilizing a simple fluorescence intensity (FI) output. It can be used on fluorescence readers typically found in academic and therapeutic research laboratories, as well as
- Published in HTS Assays, News, Products
New Transcreener CD73 Assay for Discovery of Therapeutics to Enhance Tumor Immunity
Monday, 27 April 2020
The new Transcreener CD73 Assay measures adenosine production by CD73 in a mix-and-read format with a far-red fluorescence polarization readout. The assay will accelerate efforts to discover selective CD73 antagonists for cancer immunotherapy by enabling high throughput screening, structure-driven hit-to-lead, and mechanistic studies with the purified enzyme. Madison, WI – April 27th, 2020 – Researchers
Recorded Webinar – Transcreener® CD73 Assay: Leveraging Nucleotide Detection to Measure Adenosine
Monday, 13 April 2020
CD73 is a plasma membrane-bound ectonucleotidase that hydrolyzes AMP into adenosine, contributing to immunosuppression in the tumor microenvironment; it is being pursued as a promising immuno-oncology drug target. In this webinar we will present the steps involved in development of the Transcreener CD73 assay. Transcreener is a biochemical HTS assay platform based on homogenous immunodetection